SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...

During valve-in-valve TAVI procedures using the Sapien 3 balloon-expandable valve (Edwards Lifesciences) as the second prosthesis, downsizing and underexpansion are frequently observed, particularly ...

Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation ...

In mostly women with small aortic annuli, self-expanding valves maintained superior hemodynamics and far lower valve ...

LONDON, England—Having a small or large annuli does not appear to make a difference for low-risk patients with symptomatic severe aortic stenosis, who have similar 5-year clinical and quality-of-life ...

Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were ...

Many believe that transcatheter aortic valve implantation is one of the most exciting and lucrative new technologies to hit the market providing an option for patients to sick to undergo open heart ...

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...